Pain
Austin Smith, MS
Medical Student
University of the Incarnate Word School of Osteopathic Medicine
San Antonio, Texas, United States
Aaron M. Bernal, n/a
Medical Student
University of The Incarnate Word School of Osteopathic Medicine
Boerne, Texas, United States
Jacob Nieves, BS
Medical Student
The University of Texas Medical Branch John Sealy School of Medicine
Pearland, Texas, United States
Madeleine N. Mitcham, MA
Medical Student
University of the Incarnate Word School of Osteopathic Medicine
San Antonio, Texas, United States
Aagna Patel, DO
Resident physician
Larkin Health System
Miami, Florida, United States
Roshan Santhosh, DO
Resident Physician
Larkin Health System
Miami, Florida, United States
Austin Smith, MS
University of the Incarnate Word School of Osteopathic Medicine
San Antonio, Texas, United States
Our study seeks to evaluate the safety and efficacy of suzetrigine, a novel non-opioid v1.8 sodium channel antagonist, compared with NSAIDs in patients with knee osteoarthritis.
Design:
Setting: We used TriNetX Database, which contains de-identified electronic health record data to select patients diagnosed with osteoarthritis. This study is exempt from IRB review as determined by the University of Texas Medical Branch IRB. Participants: Cohort A (NSAIDs), 735 patients; mean age of 66.3 土 12.6 years and Cohort B (SUZ), 735 patients; mean age 66.1土 11.5 years) after propensity score matching. Both cohorts had diagnoses of knee osteoarthritis. Interventions: Cohort A received non-steroidal anti-inflammatory drugs (NSAIDs) defined as receiving ketorolac plus meloxicam or naproxen or celecoxib or ketoprofen or indomethacin or diclofenac, while Cohort B received suzetrigine (SUZ) for pain relief. The findings in this retrospective analysis suggest suzetrigine shows promise as an alternative pain target by lowering rates of mu receptor analgesic use, anxiety, depression, and insomnia.
Design: Case-control retrospective cohort analysis.
Main Outcome Measures: We measured the incidence of ED visits, joint replacement, joint injections, new diagnoses of mood disorders such as depression or anxiety, insomnia, and opioid analgesic usage. Propensity score matching was utilized to mitigate potential confounders.
Results: Our investigation revealed the SUZ cohort showed lower rates of ED visits at 8.4% compared to 16.9% for the NSAID cohort (p< 0.0001). For Mu receptor analgesic use, the mean number of instances was significantly lower for the SUZ cohort (2.2) versus NSAID cohort (3.0) (p< 0.003). Rates of new diagnoses of mood disorders were lower in the SUZ cohort (8.6%) compared to the NSAID cohort (16.1%) (p< 0.0001). Rates of joint arthroplasties and injections were similar. Rates of insomnia were significantly lower in SUZ group (3.1%) compared to NSAID group (5.9%) (p< 0.012).
Conclusions:
